Wall Street Zen upgraded shares of Enliven Therapeutics (NASDAQ:ELVN – Free Report) from a sell rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.
ELVN has been the subject of several other reports. Mizuho upped their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Guggenheim reiterated a “buy” rating and set a $78.00 target price on shares of Enliven Therapeutics in a research report on Friday. The Goldman Sachs Group boosted their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, August 6th. HC Wainwright upped their price target on Enliven Therapeutics from $65.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, October 19th. Finally, Stifel Nicolaus raised their price objective on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $75.44.
Check Out Our Latest Analysis on Enliven Therapeutics
Enliven Therapeutics Trading Up 4.3%
Shares of NASDAQ:ELVN opened at $51.55 on Friday. The firm’s 50 day moving average price is $47.13 and its 200-day moving average price is $43.20. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $62.32.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.09. As a group, analysts predict that Enliven Therapeutics will post -1.79 EPS for the current fiscal year.
Insider Buying and Selling
In other news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction on Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the sale, the chief financial officer directly owned 38,000 shares in the company, valued at $1,462,240. This trade represents a 13.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director owned 13,000 shares in the company, valued at approximately $606,710. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 31,054 shares of company stock valued at $1,493,823. Company insiders own 3.00% of the company’s stock.
Institutional Investors Weigh In On Enliven Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in shares of Enliven Therapeutics in the second quarter valued at about $221,255,000. First Light Asset Management LLC grew its position in shares of Enliven Therapeutics by 574.1% during the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock worth $69,058,000 after purchasing an additional 1,158,883 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Enliven Therapeutics by 276.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock worth $52,898,000 after purchasing an additional 847,399 shares in the last quarter. Siren L.L.C. purchased a new stake in shares of Enliven Therapeutics during the first quarter worth about $29,252,000. Finally, Jupiter Topco LLC bought a new stake in Enliven Therapeutics during the 2nd quarter valued at approximately $30,617,000. 95.08% of the stock is owned by institutional investors.
About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth.
The company’s pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2.
Enliven is based in Boulder, Colorado.
Further Reading
- Five stocks we like better than Enliven Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
